If a patient had both obesity and type 2 diabetes, their GLP-1 prescription might still be covered under the diabetes diagnosis, though many plans implemented stricter documentation requirements to verify the primary treatment purpose
This supplement helps make up for that loss
However, researchers have found two solutions: development of GLP-1 analogs, which have a very similar structure to natural GLP-1 and provide all the same benefits without being broken down by DPP-4, and the development of DPP-4 inhibitors, which are drugs that prevent the enzyme from degrading natural GLP-1
It's refreshing anytime of the day
Of note, the myotendinous junction, as the weakest element in the muscle-tendon unit, its anatomy, and structural particularities were largely reviewed i.e., [1,2,23]